A phase I clinical study of Ro50-3821 - A single subcutaneous dose study

Japanese Pharmacology and Therapeutics

Volumn 38, Issue 12, 2010, Pages 1145-1157

  Tanaka, Takanori ^a,b   Sunami, Yukiko ^a,b   Fujisaki, Keiko ^a,b   Irie, Shin ^a,b   Hirashima, Kunitake ^c  

^a Ohsaki Clinic   (Japan)

^b Sumida Hospital   (Japan)

^c SAITAMA MEDICAL UNIVERSITY   (Japan)

Author keywords

C. E. R. A; CERA; Epoetin; Epoetin beta pegol (genetical recombination); Erythropoietin; ESA; Healthy volunteer; Japanese; Long acting; MICERA; PEG; Pharmacodynamics; Pharmacokinetics; Phase I; Polyethylene glycol; Ro50 3821; Safety

Indexed keywords

CONTINUOUS ERYTHROPOIESIS RECEPTOR ACTIVATOR; HEMOGLOBIN; PLACEBO; RO 50 3821; UNCLASSIFIED DRUG;

ADULT; AREA UNDER THE CURVE; ARTICLE; DOSE RESPONSE; DRUG CLEARANCE; DRUG HALF LIFE; DRUG SAFETY; DRUG TOLERABILITY; HUMAN; HUMAN EXPERIMENT; MALE; MAXIMUM PLASMA CONCENTRATION; NORMAL HUMAN; PHARMACODYNAMICS; PHASE 1 CLINICAL TRIAL; SINGLE DRUG DOSE;

EID: 79951526579     PISSN: 03863603     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (8)

1. Curran MP, McCormack PL. Methoxy polyethylene glycol-epoetin beta : a review of its use in the management of anaemia associated with chronic kidney disease. Drugs 2008 ; 68 : 1139-56. (Pubitemid 351693680)
2. Topf JM. CERA : third-generation erythropoiesis-stimulating agent. Expert Opin Pharmacother 2008 ; 9 : 839-49.
3. Macdougall IC. CERA (continuous erythropoietin receptor activator) : a new erythropoiesis-stimulating agent for the treatment of anemia. Curr Hematol Rep 2005 ; 4 : 436-40.
4. Macdougall IC, Eckardt KU. Novel strategies for stimulating erythropoiesis and potential new treatments for anaemia. Lancet 2006 : 368 : 947-53. (Pubitemid 44331359)
5. Locatelli F, Reigner B. C. E. R. A. : pharmacodynamics, pharmacokinetics and efficacy in patients with chronic kidney disease. Expert Opin Investig Drugs 2007 : 16 : 1649-61.
6. Jelkmann W. The enigma of the metabolic fate of circulating erythropoietin (Epo) in view of the pharmacokinetics of the recombinant drugs rhEpo and NESR Eur J Haematol. 2002 ; 69 : 265-74.
7. Jarsch M, Brandt M, Lanzendorfer M, Haselbeck A. Comparative erythropoietin receptor binding kinetics of C. E. R. A. and epoetin-beta determined by surface plasmon resonance and competition binding assay. Pharmacology 2008 ; 81 : 63-9.